Hepatic Vps33b deficiency aggravates cholic acid-induced cholestatic liver injury in male mice

被引:0
作者
Kai-li Fu
Pan Chen
Yan-ying Zhou
Yi-ming Jiang
Yue Gao
Hui-zhen Zhang
Li-huan Guan
Cong-hui Wang
Jun-ling Liu
Min Huang
Hui-chang Bi
机构
[1] Sun Yat-sen University,Guangdong Provincial Key Laboratory of New Drug Design and Evaluation
[2] Sun Yat-sen University,Department of Pharmacy, the First Affiliated Hospital
[3] Shanghai Jiao Tong University School of Medicine,Department of Pathophysiology
来源
Acta Pharmacologica Sinica | 2022年 / 43卷
关键词
cholestasis; liver injury; bile acids; metabonomics;
D O I
暂无
中图分类号
学科分类号
摘要
Vacuolar protein sorting 33B (VPS33B) is important for intracellular vesicular trafficking process and protein interactions, which is closely associated with the arthrogryposis, renal dysfunction, and cholestasis syndrome. Our previous study has shown a crucial role of Vps33b in regulating metabolisms of bile acids and lipids in hepatic Vps33b deficiency mice with normal chow, but it remains unknown whether VPS33B could contribute to cholestatic liver injury. In this study we investigated the effects of hepatic Vps33b deficiency on bile acid metabolism and liver function in intrahepatic cholestatic mice. Cholestasis was induced in Vps33b hepatic knockout and wild-type male mice by feeding 1% CA chow diet for 5 consecutive days. We showed that compared with the wild-type mice, hepatic Vps33b deficiency greatly exacerbated CA-induced cholestatic liver injury as shown in markedly increased serum ALT, AST, and ALP activities, serum levels of total bilirubin, and total bile acid, as well as severe hepatocytes necrosis and inflammatory infiltration. Target metabolomics analysis revealed that hepatic Vps33b deficiency caused abnormal profiles of bile acids in cholestasis mice, evidenced by the upregulation of conjugated bile acids in serum, liver, and bile. We further demonstrated that the metabolomics alternation was accompanied by gene expression changes in bile acid metabolizing enzymes and transporters including Cyp3a11, Ugt1a1, Ntcp, Oatp1b1, Bsep, and Mrp2. Overall, these results suggest a crucial role of hepatic Vps33b deficiency in exacerbating cholestasis and liver injury, which is associated with the altered metabolism of bile acids.
引用
收藏
页码:933 / 940
页数:7
相关论文
共 123 条
[1]  
Jansen PL(2009)EASL Clinical Practice Guidelines: management of cholestatic liver diseases J Hepatol 51 237-67
[2]  
Ghallab A(2017)The ascending pathophysiology of cholestatic liver disease Hepatology 65 722-38
[3]  
Vartak N(2017)New therapeutic concepts in bile acid transport and signaling for management of cholestasis Hepatology 65 1393-404
[4]  
Reif R(2018)Drug-induced cholestasis: mechanisms, models, and markers Curr Drug Metab 19 808-18
[5]  
Schaap FG(2018)Clinical guidelines for primary sclerosing cholangitis 2017 J Gastroenterol 53 1006-34
[6]  
Hampe J(2017)EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis J Hepatol 67 145-72
[7]  
Trauner M(2000)Cloning, mapping and expression analysis of VPS33B, the human orthologue of rat Vps33b Cytogenet Cell Genet 89 92-5
[8]  
Fuchs CD(2017)Vps33b is crucial for structural and functional hepatocyte polarity J Hepatol 66 1001-11
[9]  
Halilbasic E(2004)Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome Nat Genet 36 400-4
[10]  
Paumgartner G(2009)Clinical characteristics and VPS33B mutations in patients with ARC syndrome J Pediatr Gastroenterol Nutr 48 348-54